| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
(Former Name or Former Address, if Changed Since Last Report) |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and... |
| 12 Jun 2026 |
Form 4: McGaughy R Kent Jr, Director
Granted 6,500 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Matcham George, Director
Granted 6,500 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Gibson Neil W, Director
Granted 0 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Binder Gwendolyn, Director
Granted 6,500 Stock Option (Right to Buy) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Instil Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail i... |
| 15 May 2026 | 10-Q |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
DALLAS, TX, May 15, 2026 (GLOBE NEWSWIRE) - Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and prov... |
| 24 Apr 2026 | ARS |
| 24 Apr 2026 | DEFA14A |
| 24 Apr 2026 | Proxy statement: annual meeting on June 11, 2026 |
| 03 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Instil Bio, Inc.'s Form 8-K dated April 3, 2026, and have the following comments: |
| 27 Mar 2026 | S-8 |
| 27 Mar 2026 | 10-K |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development |
| 09 Feb 2026 | SCHEDULE 13G/A |
| 06 Jan 2026 |
8-K: Termination of a Material Definitive Agreement
On January 5, 2026, Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License ... |
Loading...